Pulse Biosciences, Inc. PLSE
Regular-session close
After hours · Nov 20, 4:54 PM ET
- YTD
- +231.76%
- 1 year
- +259.79%
5D -4.01 (-8.03%)
- Market cap
- 3.35B
- Revenue (ttm)
- 1.49M
- EPS (ttm)
- -1.21
- Shares out
- 73.55M
- Forward P/E
- -39.35
- YTD return
- +231.76%
- 1-year return
- +259.79%
- 50-day average
- 51.30
- 200-day average
- 33.97
- Enterprise value
- 3.08B
- Volume
- 466.85K
- Avg volume
- 503.30K
- Open
- 44.01
- Previous close
- 44.41
- Day's range
- 43.84 – 46.00
- 52-week range
- 12.70 – 58.94
- Beta
- 1.64
- Analysts
- Strong Buy
- Price target
- 67.67 (+48.6%)
- Earnings date
- Feb 18, 2027
Key statistics
- Price / sales
- 2242.41
- Price / book
- 18.19
- Revenue growth
- 359.30%
- Free cash flow
- -34.23M
- Total cash
- 189.19M
- Total debt
- 6.36M
- Return on equity
- -60.61%
- Short % of float
- 12.44%
Fundamental scorecard
5 of 25 checks passed on PLSE’s reported financials
5of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 60.00
- Target (mean)
- 67.67
- Target (high)
- 74.00
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate -0.27667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | -0.33 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.3095 | -0.32 | -0.01 | -3.39% |
| Aug 6, 2026 | Jun 30, 2026 | -0.31 | -0.36 | -0.05 | -16.13% |
| May 4, 2026 | Mar 31, 2026 | -0.32 | -0.27 | +0.05 | +15.62% |
| Feb 19, 2026 | Dec 31, 2025 | -0.265 | -0.26 | +0.01 | +1.89% |
| Nov 5, 2025 | Sep 30, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2026 | Needham | main | Buy | Buy |
| Oct 13, 2026 | Oppenheimer | main | Outperform | Outperform |
| Oct 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 23, 2026 | BTIG | init | — | Buy |
| Sep 9, 2026 | Freedom Capital Markets | init | — | Buy |
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- pulsebiosciences.com
News
Pulse Biosciences to Present at Piper Sandler 38th Annual Healthcare Conference
All You Need to Know About Pulse Biosciences (PLSE) Rating Upgrade to Buy Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $74
Needham Maintains Buy on Pulse Biosciences, Raises Price Target to $64
Pulse Biosciences Presents Six-Month Interim Results From PRECISE-BTN Thyroid Nodule Study, At 95th ATA Annual Meeting
Pulse Biosciences Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on PLSE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRETT BURKE T | Former | Sale | Dec 10, 2024 | 63,172 |
| DANAHY KEVIN PATRICK | Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 43,298 |
| DUGGAN ROBERT WILLIAM | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 49,291,700 |
| LAVIOLETTE PAUL A | Chief Executive Officer | Purchase | May 10, 2026 | 15,846 |
| UECKER DARRIN R | Chief Technology Officer | Conversion of Exercise of derivative security | Sep 16, 2025 | 284,406 |
| ZANGANEH MAHKAM | Director | Conversion of Exercise of derivative security | Feb 2, 2025 | 873,469 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Associates Inc | 3.79% | 2,789,996 | 127.08M | Sep 29, 2026 |
| Blackrock Inc. | 2.28% | 1,673,896 | 76.25M | Sep 29, 2026 |
| Citadel Advisors Llc | 2.02% | 1,484,416 | 67.62M | Sep 29, 2026 |
| Bank of America Corporation | 1.99% | 1,467,178 | 66.83M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 1.28% | 937,950 | 42.72M | Sep 29, 2026 |
| Balyasny Asset Management LP | 0.86% | 631,669 | 28.77M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.75% | 554,612 | 25.26M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.67% | 489,643 | 22.30M | Sep 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.66% | 485,300 | 22.11M | Jun 29, 2026 |
| MFS SERIES TRUST I-MFS New Discovery Fund | 0.46% | 339,453 | 15.46M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.29% | 215,880 | 9.83M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 0.29% | 214,400 | 9.77M | Jun 29, 2026 |
